Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
May 27, 2022 11:30 ET
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million
May 11, 2022 06:00 ET
|
InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company dedicated to building a portfolio of assets and...
Media Advisory: KingSett CEO Jon Love and Special Guests Rappel from Roof of 700 University Ave to Open MS Million Dollar Tower Challenge
May 05, 2022 14:22 ET
|
Multiple Sclerosis Society of Canada
Monday, May 9, 2022 – 8:30am ET 700 University Avenue (SW corner of University and College St.), Toronto, ON Live broadcast and photo opportunity from base of rappel; option for media to rappel...
With 6.3% CAGR, Multiple Sclerosis Drugs Market Size Worth USD 41.99 Billion in 2028
April 26, 2022 05:50 ET
|
Fortune Business Insights
Pune, India, April 26, 2022 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to...
Healios AG Announces Addition of Anna Walz to Board of Directors
April 12, 2022 14:00 ET
|
Healios AG
BASEL, Switzerland, April 12, 2022 (GLOBE NEWSWIRE) -- Healios AG, a MedTech company focused on developing and validating digital biomarkers since 2014, announced that Anna Walz has been appointed...
The MS Read-a-Thon Adventures Continues Through March with a $110,000 Goal
March 10, 2022 11:51 ET
|
Multiple Sclerosis Society of Canada
Toronto, O.N., March 10, 2022 (GLOBE NEWSWIRE) -- The Multiple Sclerosis (MS) Society of Canada has extended its virtual MS Read-a-Thon event until March 20, 2022, providing children and families...
Global Systemic Scleroderma Treatment Market to Surpass US$ 2,027.4 Million by 2028, Says Coherent Market Insights (CMI)
March 10, 2022 08:30 ET
|
CMI
SEATTLE, March 10, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global systemic scleroderma treatment market is estimated to be valued at US$ 1,520.1 million in 2021 and is...
AB Science annonce la publication de l’étude clinique pivot de Phase 3 du masitinib dans les formes progressives de la sclérose en plaques dans la revue Neurology® Neuroimmunology & Neuroinflammation
February 22, 2022 12:08 ET
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DE L’ETUDE CLINIQUE PIVOT DE PHASE 3 DU MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES DANS LA REVUE NEUROLOGY®: NEUROIMMUNOLOGY &...
AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
February 22, 2022 12:08 ET
|
AB Science
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS IN THE JOURNAL NEUROLOGY®: NEUROIMMUNOLOGY & NEUROINFLAMMATION Paris, 22...
AB Science a reçu l’autorisation de l’Agence de Santé Suédoise pour initier une étude confirmatoire de Phase III avec le masitinib dans les formes progressives de la sclérose en plaques
February 02, 2022 12:13 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’AUTORISATION DE L'AGENCE DE SANTÉ SUÉDOISE POUR INITIER UNE ETUDE CONFIRMATOIRE DE PHASE III AVEC LE MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLEROSE EN...